Please login to the form below

Not currently logged in
Email:
Password:

Genzyme appoints MS and rare diseases business leaders

William Sibold will head the multiple sclerosis business and Rogério Vivaldi will lead rare diseases

Genzyme has appointed leaders for its core multiple sclerosis and rare diseases businesses.

William “Bill” Sibold will head the multiple sclerosis business and Rogério Vivaldi will lead rare diseases.

“These appointments are a critical step in launching the new Genzyme,” said the company's CEO David Meeker. “Bill and Rogério are dynamic leaders with the experience, energy, vision and commitment to patients needed to move us forward.”

Sibold has more than 20 years of experience in the biopharmaceutical industry, including eight years at Biogen Idec where he worked on multiple sclerosis products Avonex and Tysabri.

He joins Genzyme from Avanir Pharmaceuticals, where he was the chief commercial officer, leading all of the company's commercial activities.

Vivaldi has been with Genzyme since 1997 and was most recently president of Genzyme's renal and endocrinology business. He previously served as senior vice president and president of Genzyme Latin America.

11th November 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics